Author

B. Martina

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1 Research Focus:variant effect prediction· 1 Organism:virus· 1

Frequent Co-Authors

A.-C. S. Vogt· 2 shared M. F. Bachmann· 2 shared M. Vogel· 2 shared X. Chang· 2 shared A. Zeltins· 1 shared D. E. Speiser· 1 shared D. Ruzek· 1 shared G. Augusto· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A.-C. S. Vogt

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Increased receptor affinity and reduced recognition by specific antibodies contribute to immune escape of SARS-CoV-2 variant Omicron

A.-C. S. Vogt, G. Augusto, B. Martina, X. Chang, G. Nasrallah, D. E. Speiser, M. Vogel, M. F. Bachmann, M. Mohsen

This study shows that SARS-CoV-2 Omicron escapes neutralizing antibodies through increased receptor affinity and reduced antibody recognition, while vaccines still provide some neutralization.

bioRxiv · Mar 11, 2022Immunology

Virus-like particles (VLPs) are efficient tools for boosting mRNA-induced antibodies

A.-C. S. Vogt, L. Jörg, B. Martina, P. S. Krenger, X. Chang, A. Zeltins, M. Vogel, M. O. Mohsen, M. F. Bachmann

This study compares antibody responses from homologous and heterologous prime-boost vaccination strategies using mRNA and VLP-based vaccines against SARS-CoV-2.

bioRxiv · Dec 20, 2021Immunology

Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19

N. S. Mulgaonkar, H. Wang, S. Mallawarachchi, D. Ruzek, B. Martina, S. Fernando

This paper reports that imatinib, an FDA-approved Bcr-Abl inhibitor, inhibits SARS-CoV-2 and other coronaviruses by blocking viral membrane fusion, suggesting its potential as a repurposed drug for COVID-19.

bioRxiv · Jun 18, 2020Microbiology